Antigenic peptides for the diagnosis and treatment of type 1 diabetes

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?-cell destruction in type 1 diabetes (T1D), none of their target […]

Bacteroides faecichinchilleae and its use in the treatment of

The invention relates to the field of probiotic and in particular to bacteria of the species Bacteroides faecichinchilleae and its use for treating […]

Lipc variant in the treatment of hypercholesterolemia and

Inventors have performed a pioneer study (Figure 5) by overexpressing control eGFP, human WT and E97G LIPC in full Ldlr-/- females fed with a […]

Methods of treatment of metabolic disorders

In the present invention SLC5A9 gene (encoding SGLT4 protein) regulation was analyzed in the intestine of patients before and after weight-loss […]

A breast-cancer cell line expressing a bret biosensor to monitor pi-3

We have developed a MCF7-derived cell line stably co-expressing the pleckstrin homology (PH) domain of Akt fused to Renilla luciferase (Luc-Akt-PH) […]

Chronopharmacoligical use of dhodh inhibitor for thetreatment and

Targeting mitochondrial function is a strategy for preventing metabolic disorders, but restoring mitochondria diurnal regulation remains to be […]

Gpr50 ligands for use for treating diseases mediated by gpr50

GPR50 (also known as MMR, H9 or ML1X), is an orphan G protein-coupled receptorbelonging to the melatonin receptor family, but which has lost the […]

Methods and pharmaceutical compositions for inducing immune tolerance

The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. […]

Antigenic peptides deriving from pcsk2 and uses thereof for the

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?-cell destruction in type 1 diabetes (T1D), none of their target […]

Antigenic peptides deriving from urocortin 3 and uses thereof for the

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?- cell destruction in type 1 diabetes (T1D), none of their target […]